Press releases
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Key statistics
As of last trade CSL Ltd (CSJ:BER) traded at 169.48, -12.73% below its 52-week high of 194.20, set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 169.24 |
---|---|
High | 169.48 |
Low | 169.24 |
Bid | 167.76 |
Offer | 171.32 |
Previous close | 170.40 |
Average volume | 41.43 |
---|---|
Shares outstanding | 483.25m |
Free float | 481.01m |
P/E (TTM) | 35.47 |
Market cap | 133.28bn AUD |
EPS (TTM) | 7.78 AUD |
Annual div (ADY) | 2.36 EUR |
---|---|
Annual div yield (ADY) | 1.38% |
Div ex-date | Mar 11 2024 |
Div pay-date | Apr 03 2024 |
Data delayed at least 15 minutes, as of May 06 2024 10:22 BST.
More ▼